Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
66.5 EUR | 0.00% |
|
+0.76% | -31.09% |
Jul. 05 | DZ Bank Downgrades Carl Zeiss Meditec to Hold from Buy, Cuts PT | MT |
Jul. 03 | Berenberg lowers target for Carl Zeiss Meditec to 71 euros - 'Hold' | DP |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analyst opinion has improved significantly over the past four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 30.69 times its estimated earnings per share for the ongoing year.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-31.09% | 6.35B | - | ||
+1.04% | 205B | B | ||
+4.02% | 178B | B- | ||
+31.77% | 158B | B- | ||
+31.66% | 112B | A- | ||
+1.52% | 64.58B | A- | ||
+20.45% | 55.34B | B+ | ||
-3.54% | 46.64B | B+ | ||
-9.32% | 36.78B | A | ||
-1.25% | 34.85B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- AFX Stock
- AFXA Stock
- Ratings Carl Zeiss Meditec AG